Key result
Higher CA125 is linked to ~2.7-fold higher odds of severe systemic venous congestion in ADHF.
Why the study?
CA125 is a biomarker of congestion and venous excess ultrasound noninvasively assesses systemic venous congestion, prompting evaluation of the association between CA125 and congestion severity by a modified VExUS protocol in patients hospitalized with ADHF.
Does carbohydrate antigen-125 (CA125) correlate with and discriminate severe systemic venous congestion assessed by modified venous excess ultrasound (mVExUS) in patients hospitalized with acute decompensated heart failure?
Observational (n=112)
No
Does carbohydrate antigen-125 (CA125) correlate with and discriminate severe systemic venous congestion assessed by modified venous excess ultrasound (mVExUS) in patients hospitalized with acute decompensated heart failure?
Higher CA125 levels are independently associated with severe systemic venous congestion as defined by mVExUS grade 3 in patients hospitalized with acute decompensated heart failure, offering moderate discriminatory power and complementary diagnostic value.
Answers are grounded in this paper and cite their sources.
CA125 may aid congestion assessment in acute HF; hypothesis-generating and should not yet change practice.
Background and Objectives: Systemic venous congestion is a key feature of acute decompensated heart failure (ADHF). Carbohydrate antigen-125 (CA125) is a biomarker of congestion, whereas venous excess ultrasound provides a noninvasive assessment of systemic venous congestion. We evaluated the association between CA125 and congestion severity assessed by a modified venous excess ultrasound (mVExUS) protocol in patients hospitalized with ADHF. Materials and Methods: This single-center observational study included 112 consecutive patients with ADHF. mVExUS was based on inferior vena cava diameter and hepatic and portal venous Doppler patterns. mVExUS was evaluable in 108 patients, CA125 was available in 106, and 102 had both measurements. The full mVExUS spectrum was examined; grade 3 versus grades 0–2 was used for regression and discrimination analyses. Results: Median CA125 concentrations across mVExUS grades 0, 1, 2, and 3 were 63 (17–210), 61 (20–127), 48.5 (21.5–60), and 151 (88.8–331.8) U/mL, respectively (p < 0.001). Ordinal mVExUS grade correlated with CA125 (ρ = 0.42, p < 0.001). After adjustment for age, sex, eGFR, atrial fibrillation, and severe tricuspid regurgitation, ln (CA125) remained associated with mVExUS grade 3 (adjusted OR 2.73, 95% CI 1.56–4.77; p < 0.001). CA125 showed moderate discrimination for grade 3 congestion (AUC 0.790, 95% CI 0.704–0.873); a threshold of 73 U/mL yielded 80.4% sensitivity and 69.6% specificity. Grade 3 patients also had a longer hospital stay (11 (9–15) vs. 7 (6–12) days; p = 0.001). Conclusions: Higher CA125 levels were associated with severe mVExUS-defined systemic venous congestion. CA125 and mVExUS may provide complementary information, although the derived threshold requires external validation.
No takes yet. Share an insight, caveat, or question.
Kozluca et al. (2026) conducted an observational in Acute decompensated heart failure (ADHF) (n=112). Carbohydrate antigen-125 (CA125) concentration (per ln increase) vs. mVExUS grades 0-2 (vs grade 3) was evaluated on Severe systemic venous congestion defined as modified venous excess ultrasound (mVExUS) grade 3 (vs grades 0-2) (OR 2.73, 95% CI 1.56-4.77, p=<0.001). Higher ln(CA125) was independently associated with mVExUS grade 3 congestion in ADHF.
Synapse has enriched 10 related papers. Consider them for comparative context: